Global Regulatory Network Validant has expanded into a global regulatory brand through the ELIQUENT Life Sciences alliance, creating a broader, integrated offering across pharmaceuticals, biologics, medical devices, and diagnostics. This presents opportunities to cross-sell via a unified regulatory services approach to clients seeking end-to-end compliance and lifecycle regulatory support.

Mature Growth With Leadership Recent leadership appointments and strategic hires (CEO Tim Dietlin and Partner Joseph Jimenez) signal an inflection toward accelerated growth and deeper client engagement. Propose executive-level conversations to align regulatory strategy with expanding product portfolios and faster time-to-market.

Acquisition-Driven Capabilities Historical acquisitions (COS, Oriel STAT A MATRIX, IDEC, Clinoutsolutions) have broadened capabilities in COA, medical device regulatory, and global regulatory consulting. Target opportunities to upsell integrated quality, compliance, and launch readiness services to existing clients of these acquired firms.

Lifecycle Compliance Focus Validant’s end-to-end lifecycle support from preclinical to manufacturing and distribution highlights a need for continuous regulatory alignment, quality systems, and digital governance. Sales plays could emphasize ongoing regulatory intelligence, change management, and post-market surveillance services.

Mid-Market Global Reach With 51-200 employees and a $100M-$250M revenue band, Validant sits between niche boutiques and mega-labs, offering scalable regulatory resources worldwide. Identify mid-market life science companies planning global launches or complex device combinations as prime targets for scalable regulatory and quality solutions.